InvestSMART

Bio-Gene Technology Ltd (ASX: BGT) - Announcements

Current share price for BGT : $0.016 0.001 (6.67%)+

ASX company news and announcements for Bio-Gene Technology Ltd (BGT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bio-Gene Technology Ltd (BGT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bio-Gene Technology Ltd (BGT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bio-Gene Technology Ltd (BGT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Placement Update and Section 708A(5)(e) Notice 2 Jun 2026 9:48AM $0.022 $0.016 fallen by 27.27%
$7 Application for quotation of securities - BGT 2 Jun 2026 9:40AM $0.022 $0.016 fallen by 27.27%
$7 Proposed issue of securities - BGT 2 Jun 2026 9:33AM $0.022 $0.016 fallen by 27.27%
$7 Proposed issue of securities - BGT 26 May 2026 10:01AM $0.029 $0.016 fallen by 44.83%
$7 Proposed issue of securities - BGT 26 May 2026 10:01AM $0.029 $0.016 fallen by 44.83%
$7 Investor Presentation - Placement 26 May 2026 10:01AM $0.029 $0.016 fallen by 44.83%
$7 Results of Placement 26 May 2026 9:59AM $0.029 $0.016 fallen by 44.83%
$7 Trading Halt 22 May 2026 9:28AM $0.029 $0.016 fallen by 44.83%
$7 BGT to expand Flavocide and Qcide evaluation to Asia 21 May 2026 8:34AM $0.027 $0.016 fallen by 40.74%
$7 Key insecticide combinations patent allowed in the US 6 May 2026 9:49AM $0.038 $0.016 fallen by 57.89%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2026 11:55AM $0.038 $0.016 fallen by 57.89%
$7 Investor Presentation 20 Apr 2026 9:32AM $0.038 $0.016 fallen by 57.89%
$7 Change of Auditor 14 Apr 2026 9:33AM $0.035 $0.016 fallen by 54.29%
$7 NWR Healthcare Conference Presentation 26 Mar 2026 12:20PM $0.035 $0.016 fallen by 54.29%
$7 Bio-Gene to present at NWR Healthcare Conference 20 Mar 2026 9:58AM $0.034 $0.016 fallen by 52.94%
$7 Sumitomo & Nakashima to launch Qcide products in Japan 16 Mar 2026 8:18AM $0.035 $0.016 fallen by 54.29%
$7 Update on Qcide Production 10 Mar 2026 9:28AM $0.035 $0.016 fallen by 54.29%
$7 Regulatory Development of Flavocide 3 Mar 2026 9:05AM $0.033 $0.016 fallen by 51.52%
$7 Appendix 4D and Half-Year Accounts 31 December 2025 24 Feb 2026 9:35AM $0.031 $0.016 fallen by 48.39%
$7 Flavocide Acute Neurotoxicity Study Underway 13 Feb 2026 9:45AM $0.031 $0.016 fallen by 48.39%
$7 Flavocide Reproductive Toxicity Study Underway 9 Feb 2026 9:31AM $0.033 $0.016 fallen by 51.52%
$7 CFO and Company Secretary Appointment/Resignation 2 Feb 2026 9:11AM $0.035 $0.016 fallen by 54.29%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:24AM $0.031 $0.016 fallen by 48.39%
$7 U.S. Department of Defense Grant Programs Advance 18 Dec 2025 8:53AM $0.023 $0.016 fallen by 30.43%
$7 Outcome of review of Continuous Disclosure Procedures 2 Dec 2025 8:21AM $0.026 $0.016 fallen by 38.46%

26 - 50 of 485 results

Page 2 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.